Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

ortfolio will continue to drive total revenue growth; however, the rate of growth will reduce in the fourth quarter as we will not benefit from the one off adjustment to ADDERALL XR Medicaid rebates and high level of royalties experienced in the same period last year. The consolidation of Movetis will also mean that combined R&D and SG&A spend for 2010 is likely to grow at marginally above 10% year on year.

Shire has made significant progress in 2010. Growth across our core portfolio, particularly the accelerated growth of our HGT business, has enabled us to increase our expectations of earnings while also making targeted investments in our pipeline and international structure. We expect to see solid earnings growth in 2011, but at a rate that reflects the pull ahead into 2010 of some of HGT's growth potential.

PRODUCT LAUNCHES

Subject to obtaining the relevant regulatory/governmental approvals, future product launches in the next 12 months include:

- VYVANSE/VENVANSE for the treatment of Attention Deficit Hyperactivity Disorder ("ADHD") in adolescents in the US and children in Brazil; - INTUNIV as adjunctive treatment to long acting oral stimulants for the treatment of ADHD in children and adolescents in the US; - EQUASYM(R) for the treatment of ADHD in certain European Union ("EU") countries; - RESOLOR(R) in certain EU countries, for the symptomatic treatment of chronic constipation in women for whom laxatives fail to provide adequate relief; - LIALDA/MEZAVANT for the maintenance of remission of ulcerative colitis in the US and for the treatment of ulcerative colitis in certain countries; - VPRIV for the treatment of type 1 Gaucher disease in certain European and Latin American countries; and - FIRAZYR(R) for the symptomatic treatment of acute attacks of hereditary angioedema ("HAE") in the US and certain European and Latin American countries. PRODUCT AND PIPELINE DEVELOPMENTS Products PENTASA(R) - for the treatment of Ulcer
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)... MARLBOROUGH, Mass. , May 27, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today provided an update on the status of ... Stock. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... there were 3,085 and 21 shares of Series ...
(Date:5/27/2015)... ­ Caris Life Sciences®, a leading biotechnology ... today announced it has appointed the Levine Cancer Institute, ... site in the Caris Centers of Excellence for Precision ... is one of the largest cancer care providers throughout ... patients annually. Derek Raghavan , M.D., Ph.D., President ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... HARBIN, China , May ... ("China Sky One Medical" or "the Company") (Nasdaq: ... producing over-the-counter drugs in, the People,s Republic of ... Long,Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal,of ...
... NEW YORK , May 27 Pfizer Inc. (NYSE: ... to the EMPHASIS-HF trial early on the recommendations of the trial,s ... analysis by the independent Data Safety Monitoring Committee (DSMC) of the ... early according to the protocol pre-defined stopping rules. , ...
... in the College of Engineering at Virginia Tech, has ... to support development of a carbon nanotube-enhanced composite for ... huge wind turbine blades. Powe awards provide seed ... member institutions. These awards are intended to enrich the ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 2Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 4Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Biological and Environmental Nanotechnology (CBEN) have developed a ... human cell that is programmed to light up ... of particular proteases is a common hallmark of ... the September issue of the journal Biochemical and ...
... The most detailed analysis to date of how humans differ ... that natural selection has shaped the recent evolution of our ... Celera Diagnostics. , In a study published in the ... 11,624 genes, comparing how genes vary not only among 39 ...
... a 'living gel' that could be applied to the ... , The researchers genetically modified bacteria that are normally ... protein that stops the HIV virus from infecting cells. ... the internal body surfaces where HIV transmission can occur ...
Cached Biology News:'Smart' nanoprobes light up disease 2Cornell finds natural selection in humans 2Cornell finds natural selection in humans 3Living anti-HIV gel shows early promise 2